233278-53-0

Upstream product

• 107228-57-9 3,6-dichloro-4-cyclobutylpyridazine 
• 613-94-5 benzoic acid hydrazide 

Downstream Products

• 233278-42-7 N'-(7-cyclobutyl-3-phenyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-N,N-dimethylethane-1,2-diamine 
• 202931-99-5 7-Cyclobutyl-3-phenyl-1,2,4-triazolo[4,3-b]pyridazin-6-one 
• 473382-39-7 Akt-l-1 
• 1055262-88-8 N₁-(7-cyclobutyl-3-phenyl-[1,2,4]triazole[4,3-b]pyridine-6-yl)-2,2-dimethyl-N₃-(pent-4-ynyl)propane-1,3-diamine 
• 233278-35-8 N-(7-Cyclobutyl-3-phenyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-N-methyl-N-(1-methyl-1H-1,2,4-triazol-3-ylmethyl)amine Hydrochloride 
• 233278-52-9 N-(7-cyclobutyl-3-phenyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-N,N-dimethylamine 
• 233278-37-0 7-cyclobutyl-3-phenyl-1,2,4-triazolo[4,3-b]pyridazin-6-ylamine 
• 233278-39-2 7-cyclobutyl-6-(morpholin-4-yl)-3-phenyl-1,2,4-triazolo[4,3-b]pyridazine 

Relevant academic research and scientific papers

BIVALENT INHIBITORS OF AKT PROTEIN KINASE

The present disclosure describes compounds which are Akt kinase inhibitors useful for the treatment of cancer. The compounds disclosed herein are bivalent ligands capable of binding with both the kinase enzyme ATP binding domain and the kinase enzyme subs

Triazolo-pyridazine derivatives as ligands for GABA receptors

1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent as the 3-position and an amino moiety at the 6-position, are selective ligands for GABAAreceptors, in particular having high affinity for the α2 and/or α3 subunit thereof, are useful in the treatment of anxiety and convulsions.